Supreme Court To Hear Oral Arguments in Landmark Patent Case

by Baker Donelson

April 15 is a big day for biotechnology, pharmaceutical, and medical diagnostic companies at the Supreme Court, as justices begin a new session by hearing oral arguments in a landmark case involving the patentability of isolated nucleic acids in Association for Molecular Pathology, et al. v. Myriad Genetics, et al.

Since at least the 1980s, the United States Patent and Trademark Office (USPTO) has granted patents on "isolated nucleic acids," including nucleic acids that correspond to human gene sequences. According to the USPTO, nucleic acids do not naturally exist in an isolated state, thus isolated nucleic acids are purely human-made compositions. Isolated nucleic acids are therefore patent-eligible as long as they have a specific and substantial practical utility. These patents are incredibly important to biotechnology, pharmaceutical and molecular diagnostics companies, as they are the most effective way (and often the only way) to recoup the substantial R&D investments required to develop new therapeutics and diagnostic tests.

Myriad Genetics and Laboratories, Inc. owns a patent covering isolated nucleic acids corresponding to the gene sequence of BRCA1, a gene locus related to breast cancer. Myriad’s nucleic acids are useful as probes for detecting mutations in this locus that correlate with a high risk of breast cancer. The American Civil Liberties Union (ACLU), on behalf of several medical groups, patient advocacy groups and individual patients and doctors, challenged the validity of this patent, arguing that naturally occurring nucleotide sequences cannot be patent-eligible simply by isolating them, because their functionality is defined by their naturally-occurring sequence.

The U.S. District Court for the Southern District of New York agreed with the ACLU, holding that the patents are invalid for relating to patent-ineligible natural products. The Court of Appeals for the Federal Circuit reversed that decision, generating three separate opinions.

Speaking for the court, Judge Alan D. Lourie reasoned that isolated nucleic acids are patent-eligible because their isolation requires peptide binds to be broken, resulting in a distinct chemical entity. Judge Kimberly A. Moore, in concurrence, reasoned that isolation of natural products can result in patent-eligible subject matter, but only if the isolation is linked to a substantial new utility that is distinct from the product's natural function. Thus, if decided on a blank slate, Judge Moore would have found "fragments" of a naturally occurring nucleotide sequence to be patent-eligible, because they have various uses in isolation that they would not have in nature, but the full-length gene sequence would not be patent-eligible because the only substantial use is to express a protein, which is what it does in nature. Nonetheless, because the government acquiesced in the issuance of such patents for so long, she concurred in judgment with Judge Lourie to avoid upsetting the "settled expectations of the patenting community."

Judge William C. Bryson dissented in part, reasoning that isolation of the naturally-occurring product is patent-ineligible unless some "essential character" of the natural product has been changed. Contiguous nucleotide sequences that occur in nature therefore are patent-ineligible because any utility they may have is a consequence of the naturally-occurring sequence.

Immatics Biotechnologies, GmbH and Baker Donelson submitted an amicus brief in support of Myriad. In particular, we reasoned that Supreme Court precedent only requires that the natural product be presented in a "new form capable of use and designed to be used in such new form," which is satisfied by showing that isolation places the product into a form that is capable of a substantial utility. Importantly, this test does not require either a change in the chemical composition or a change in the function of the natural product. We further emphasized the importance of these products to the biotechnology industry, and the potential economic consequences of an adverse decision. The amicus brief can be found here.

The Supreme Court is scheduled to hear oral arguments in Association for Molecular Pathology, et al. v. Myriad Genetics on April 15. If you have questions about how this decision can affect your company, or if you have any other intellectual property questions, please contact any of these attorneys in our Intellectual Property Group. 

Atlanta, Georgia
Carl M. Davis 678.406.8703
Dorian B. Kennedy 678.406.8705
Michael J. Powell 678.406.8707
Clint Crosby Jr. 678.406.8702

Baton Rouge, Louisiana
Warner Joseph Delaune 225.381.7032

Chattanooga, Tennessee
Micheline Kelly Johnson 423.209.4103

Knoxville, Tennessee
Peter L. Brewer 865.971.5102
Thomas A. Hodge 678.406.8706

Memphis, Tennessee
Julie R. Baldridge 901.577.8132

Nashville, Tennessee
W. Edward Ramage 615.726.5771

Washington, D.C.
Richard E. L. Henderson, Ph.D. 202.508.3400
D. Christopher Holly, Ph.D. 202.508.3451
Shazi Jiang, M.D. 202.508.3420
Bryan W. Jones 202.508.3428
Susan E. McBee 202.508.3450
Chester G. Moore, Ph.D. 202.654.4627
David L. Vanik, Ph.D. 202.508.3406
David W. Woodward 202.508.3423


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Baker Donelson | Attorney Advertising

Written by:

Baker Donelson

Baker Donelson on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.